CD274 and neoplasm: Antigenicity biomarkers, including high microsatellite instability (MSI‐H) and high tumor mutation burden (TMB), and inflammatory biomarkers of the tumor microenvironment, including PD‐L1 expression and T‐cell inflamed gene expression profile (GEP) appeared as rational and promising options [58].